Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress

Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder for which no effective treatment is available. Studies have demonstrated that improving insulin resistance in type 2 diabetes mellitus (T2DM) can benefit patients with PD. In addition, a neuroprotective effect of glucag...

Full description

Saved in:
Bibliographic Details
Main Authors: Dong-xing Liu, Chen-sheng Zhao, Xiao-na Wei, Yi-peng Ma, Jian-kun Wu
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Parkinson's Disease
Online Access:http://dx.doi.org/10.1155/2022/6813017
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832551209676832768
author Dong-xing Liu
Chen-sheng Zhao
Xiao-na Wei
Yi-peng Ma
Jian-kun Wu
author_facet Dong-xing Liu
Chen-sheng Zhao
Xiao-na Wei
Yi-peng Ma
Jian-kun Wu
author_sort Dong-xing Liu
collection DOAJ
description Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder for which no effective treatment is available. Studies have demonstrated that improving insulin resistance in type 2 diabetes mellitus (T2DM) can benefit patients with PD. In addition, a neuroprotective effect of glucagon-like peptide-1 (GLP-1) receptor agonists was demonstrated in experimental models of PD. In addition, there are some clinical trials to study the neuroprotective effect of GLP-1 analog on PD patients. Semaglutide is a long-acting, once-a-week injection treatment and the only available oral form of GLP-1 analog. In the present study, we treated the human neuroblastoma SH-SY5Y cell line with 6-hydroxydopamine (6-OHDA) as a PD in vitro model to explore the neuroprotective effects and potential mechanisms of semaglutide to protect against PD. Moreover, we compared the effect of semaglutide with liraglutide given at the same dose. We demonstrated that both semaglutide and liraglutide protect against 6-OHDA cytotoxicity by increasing autophagy flux and decreasing oxidative stress as well as mitochondrial dysfunction in SH-SY5Y cells. Moreover, by comparing the neuroprotective effects of semaglutide and liraglutide on PD cell models at the same dose, we found that semaglutide was superior to liraglutide for most parameters measured. Our results indicate that semaglutide, the new long-acting and only oral GLP-1 analog, may be represent a promising treatment for PD.
format Article
id doaj-art-b3bb6c09b5b64328bc7ea9b87a43fe50
institution Kabale University
issn 2042-0080
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Parkinson's Disease
spelling doaj-art-b3bb6c09b5b64328bc7ea9b87a43fe502025-02-03T06:04:49ZengWileyParkinson's Disease2042-00802022-01-01202210.1155/2022/6813017Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative StressDong-xing Liu0Chen-sheng Zhao1Xiao-na Wei2Yi-peng Ma3Jian-kun Wu4Department of NeurologyDepartment of NeurologyDepartment of NeurologyDepartment of NeurologyDepartment of NeurologyParkinson’s disease (PD) is the second most prevalent neurodegenerative disorder for which no effective treatment is available. Studies have demonstrated that improving insulin resistance in type 2 diabetes mellitus (T2DM) can benefit patients with PD. In addition, a neuroprotective effect of glucagon-like peptide-1 (GLP-1) receptor agonists was demonstrated in experimental models of PD. In addition, there are some clinical trials to study the neuroprotective effect of GLP-1 analog on PD patients. Semaglutide is a long-acting, once-a-week injection treatment and the only available oral form of GLP-1 analog. In the present study, we treated the human neuroblastoma SH-SY5Y cell line with 6-hydroxydopamine (6-OHDA) as a PD in vitro model to explore the neuroprotective effects and potential mechanisms of semaglutide to protect against PD. Moreover, we compared the effect of semaglutide with liraglutide given at the same dose. We demonstrated that both semaglutide and liraglutide protect against 6-OHDA cytotoxicity by increasing autophagy flux and decreasing oxidative stress as well as mitochondrial dysfunction in SH-SY5Y cells. Moreover, by comparing the neuroprotective effects of semaglutide and liraglutide on PD cell models at the same dose, we found that semaglutide was superior to liraglutide for most parameters measured. Our results indicate that semaglutide, the new long-acting and only oral GLP-1 analog, may be represent a promising treatment for PD.http://dx.doi.org/10.1155/2022/6813017
spellingShingle Dong-xing Liu
Chen-sheng Zhao
Xiao-na Wei
Yi-peng Ma
Jian-kun Wu
Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress
Parkinson's Disease
title Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress
title_full Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress
title_fullStr Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress
title_full_unstemmed Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress
title_short Semaglutide Protects against 6-OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress
title_sort semaglutide protects against 6 ohda toxicity by enhancing autophagy and inhibiting oxidative stress
url http://dx.doi.org/10.1155/2022/6813017
work_keys_str_mv AT dongxingliu semaglutideprotectsagainst6ohdatoxicitybyenhancingautophagyandinhibitingoxidativestress
AT chenshengzhao semaglutideprotectsagainst6ohdatoxicitybyenhancingautophagyandinhibitingoxidativestress
AT xiaonawei semaglutideprotectsagainst6ohdatoxicitybyenhancingautophagyandinhibitingoxidativestress
AT yipengma semaglutideprotectsagainst6ohdatoxicitybyenhancingautophagyandinhibitingoxidativestress
AT jiankunwu semaglutideprotectsagainst6ohdatoxicitybyenhancingautophagyandinhibitingoxidativestress